Skip to content

Study · Observational study · n = 52 · 2020

4 results

Teriparatide treatment increases Hounsfield units in the lumbar spine out of proportion to DEXA changes.

Mikula AL, Puffer RC, Jeor JDS, Bernatz JT, Fogelson JL, Larson AN, Nassr A, Sebastian AS, Freedman BA, Currier BL, Bydon M, Yaszemski MJ, Anderson PA, Elder BD

Journal of neurosurgery. Spine18 Oct 2019Cited by 32 (Europe PMC)

PMID31628287 (opens in a new tab)DOI10.3171/2019.7.spine19654 (opens in a new tab)PepBankPUB-31628287
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In a retrospective patient cohort, teriparatide treatment was linked to increased lumbar spine Hounsfield units from baseline.

    In plain wordsIn a retrospective patient cohort, teriparatide treatment was linked to higher lumbar scan density than before treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine Hounsfield units
    Study

    n = 52

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 20.9 ± 6.5 monthsAs given in this study (human).

    Measurements

    Lumbar HU
    109.8 HU
    before treatment
    Lumbar HU
    133.9 HU
    after treatment
    HU increase
    22%
    from baseline

    Source sentences

    Summary
    The mean ± standard deviation HU increase throughout the lumbar spine (L1-4) was from 109.8 ± 53 to 133.9 ± 61 HU (+22%, 95% CI 1.2-46, p value = 0.039).
    3 context sentences
    Summary · context
    A retrospective chart review was performed from 1997 to 2018 across all campuses at our institution.
    Summary · context
    The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.
    Summary · context
    Fifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy.
  2. 02HumanObservational studyEfficacy outcome

    In a retrospective patient cohort, teriparatide treatment was linked to increased lumbar spine BMD from baseline.

    In plain wordsIn a retrospective patient cohort, teriparatide treatment was linked to higher lumbar bone density than before treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 52

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 20.9 ± 6.5 monthsAs given in this study (human).

    Measurements

    Lumbar BMD
    0.85 g/cm2
    before treatment
    Lumbar BMD
    0.93 g/cm2
    after treatment
    BMD increase
    9%
    from baseline

    Source sentences

    Summary
    Based on DEXA results, lumbar spine BMD increased from 0.85 to 0.93 g/cm2 (+9%, p value = 0.044).
    3 context sentences
    Summary · context
    A retrospective chart review was performed from 1997 to 2018 across all campuses at our institution.
    Summary · context
    The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.
    Summary · context
    Fifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy.
  3. 03HumanObservational studyEfficacy outcome

    In a retrospective patient cohort, teriparatide treatment was linked to improved lumbar spine T-scores from baseline.

    In plain wordsIn a retrospective patient cohort, teriparatide treatment was linked to better lumbar bone density scores than before treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine T-score
    Study

    n = 52

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 20.9 ± 6.5 monthsAs given in this study (human).

    Measurements

    Lumbar T-score
    −2.4 T-score
    before treatment
    Lumbar T-score
    −1.7 T-score
    after treatment

    Source sentences

    Summary
    Lumbar spine T-scores improved from -2.4 ± 1.5 to -1.7 ± 1.5 (p value = 0.03).
    3 context sentences
    Summary · context
    A retrospective chart review was performed from 1997 to 2018 across all campuses at our institution.
    Summary · context
    The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.
    Summary · context
    Fifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy.
  4. 04HumanObservational studyEfficacy outcome

    In a retrospective patient cohort, femoral neck T-score changes during teriparatide treatment were not significant.

    In plain wordsIn a retrospective patient cohort, femoral neck bone density scores did not change significantly from before teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFemoral neck T-score
    Study

    n = 52

    Comparator
    Before teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 20.9 ± 6.5 monthsAs given in this study (human).

    Measurements

    Femoral neck T-score
    −2.5 T-score
    before treatment
    Femoral neck T-score
    −2.3 T-score
    after treatment

    Source sentences

    Summary
    Average femoral neck T-scores improved from -2.5 ± 1.1 to -2.3 ± 1.0 (p value = 0.31).
    3 context sentences
    Summary · context
    A retrospective chart review was performed from 1997 to 2018 across all campuses at our institution.
    Summary · context
    The authors identified patients who had been treated with at least 6 months of teriparatide and compared HU and BMD as measured on DEXA scans before and after treatment.
    Summary · context
    Fifty-two patients were identified for analysis (46 women and 6 men, average age 67 years) who underwent an average of 20.9 ± 6.5 months of teriparatide therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.